Literature DB >> 15131463

Impact of wheezing after respiratory syncytial virus infection on health-related quality of life.

Louis Bont1, Marijke Steijn, Wim M C van Aalderen, Jan L L Kimpen.   

Abstract

BACKGROUND: Respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) is often followed by recurrent wheezing episodes during childhood. The effect of postbronchiolitis wheezing on the well-being of the child is not known. This study aimed to determine the impact of RSV LRTI hospitalization before age 13 months on health-related quality of life (HRQoL) at age 3 years.
METHODS: HRQoL was measured in a previously described cohort of children with a history of RSV infection and compared with control term children from the open population. HRQoL was determined during the winter season in index and control children. We used a validated questionnaire, which measures the health status of children in 13 domains weighted by the impact of the health status problems on well-being. The lung domain was the focus of this study. In addition daily respiratory symptoms of the index children were recorded prospectively up to age 3 years and correlated with HRQoL scores.
RESULTS: HRQoL was lower in index children (n = 128) than in control children (n = 340) for the lung, gastrointestinal tract and sleeping domains. HRQoL scores for social and developmental domains were similar for index and control children. As anticipated the largest difference between index and control children was found in the lung domain (77.6 +/- 2.2 vs. 93.9 +/- 0.8, P < 0.01). HRQoL in the lung domain was lower during the winter than during the summer season (77.6 +/- 2.2 vs. 85.6 +/- 1.9, P < 0.01), which was explained by increased airway morbidity during the winter season. We found a high correlation between lung HRQoL scores and total number of wheezing days during follow-up.
CONCLUSIONS: Postbronchiolitis wheezing has broad implications for long-term well-being of children. Decreased HRQoL was attributed to postbronchiolitis wheezing, but not to preexistent risk factors, such as premature birth. This study underscores the importance of developing new strategies to prevent and treat long term airway morbidity after RSV LRTI.

Entities:  

Mesh:

Year:  2004        PMID: 15131463     DOI: 10.1097/01.inf.0000122604.32137.29

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  18 in total

1.  Discovery of a Potent Dual Inhibitor of Wild-Type and Mutant Respiratory Syncytial Virus Fusion Proteins.

Authors:  Toru Yamaguchi-Sasaki; Seiken Tokura; Yuya Ogata; Takanori Kawaguchi; Yutaka Sugaya; Ryo Takahashi; Kanako Iwakiri; Tomoko Abe-Kumasaka; Ippei Yoshida; Kaho Arikawa; Hiroyuki Sugiyama; Kosuke Kanuma
Journal:  ACS Med Chem Lett       Date:  2020-04-10       Impact factor: 4.345

2.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

Review 3.  Mechanisms how mucosal innate immunity affects progression of allergic airway disease.

Authors:  Allan R Brasier
Journal:  Expert Rev Respir Med       Date:  2019-02-13       Impact factor: 3.772

4.  Longitudinal study of quality of life among children with acute respiratory infection and cough.

Authors:  Yolanda G Lovie-Toon; Anne B Chang; Peter A Newcombe; Dimitrios Vagenas; Sophie Anderson-James; Benjamin J Drescher; Michael E Otim; Kerry-Ann F O'Grady
Journal:  Qual Life Res       Date:  2018-01-22       Impact factor: 4.147

5.  Central Role of the NF-κB Pathway in the Scgb1a1-Expressing Epithelium in Mediating Respiratory Syncytial Virus-Induced Airway Inflammation.

Authors:  Bing Tian; Jun Yang; Yingxin Zhao; Teodora Ivanciuc; Hong Sun; Maki Wakamiya; Roberto P Garofalo; Allan R Brasier
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

6.  A Review of the CD4+ T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population.

Authors:  Ravi S Misra
Journal:  EC Microbiol       Date:  2014

Review 7.  Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age.

Authors:  X Carbonell-Estrany; L Bont; G Doering; J-B Gouyon; M Lanari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-07-16       Impact factor: 3.267

8.  Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand.

Authors:  K Grimwood; C Cohet; F J Rich; S Cheng; C Wood; N Redshaw; C W Cunningham; N Pearce; J R Kirman
Journal:  Epidemiol Infect       Date:  2008-01-04       Impact factor: 2.451

9.  Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze.

Authors:  Annemieke Schuurhof; Riny Janssen; Hanneke de Groot; Hennie M Hodemaekers; Arja de Klerk; Jan Ll Kimpen; Louis Bont
Journal:  Respir Res       Date:  2011-09-12

10.  The effect of high dose inhaled corticosteroids on wheeze in infants after respiratory syncytial virus infection: randomised double blind placebo controlled trial.

Authors:  Marieke J J Ermers; Maroeska M Rovers; Job B van Woensel; Jan L L Kimpen; Louis J Bont
Journal:  BMJ       Date:  2009-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.